The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Viatris is leaving the biosimilar field just months after winning the landmark FDA approval for the first interchangeable biosimilar product. Biocon Biologics, a subsidiary of Biocon, will buy Viatris ...

Biocon Biologics announced that it will be acquiring Viatris’ biosimilars portfolio for close to $3 billion. Biocon Biologics announced that it will be acquiring Viatris’ biosimilars portfolio for ...

Viatris has signed definitive agreements for the sale of its equity stake in Biocon Biologics to Biocon for $815m. Viatris will sell all of its convertible preferred equity in Biocon Biologics. The ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min One of a number of divestitures ...

Viatris (VTRS) on Saturday said that it has entered into definitive agreements with Biocon for the sale of Viatris' equity stake in Biocon Biologics Limited. Under the definitive agreements, Biocon ...

Viatris is letting go of the equity stake it’s held in Biocon’s biosimilar subsidiary Biocon Biologics for $815 million, allowing Biocon to fully integrate its subsidiary. The Viatris stake is one of ...

Despite trading at low multiples, Viatris is exposed to macroeconomic headwinds, regulatory pressures, and a $500M revenue hit from FDA actions, increasing downside risk. Recent impairments and the ...

Feb 28 (Reuters) - Shares of Indian drugmaker Biocon Ltd (BION.NS), opens new tab fell about 12% on Monday after the company said its unit Biocon Biologics would buy U.S.-based Viatris Inc's (VTRS.O), ...

The transaction accelerates the expiration of biosimilars non-compete restrictions, the company said. The shares are subject to a six-month lock up period. Transaction value will be subject to related ...